Byunghee Yoo1, Amol Kavishwar1, Alana Ross1, Pamela Pantazopoulos1, Anna Moore2,3, Zdravka Medarova4,5. 1. Molecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA. 2. Molecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA. amoore@helix.mgh.harvard.edu. 3. Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA. amoore@helix.mgh.harvard.edu. 4. Molecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA. zmedarova@mgh.harvard.edu. 5. Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA. zmedarova@mgh.harvard.edu.
Abstract
PURPOSE: The development of tools for the analysis of microRNA (miRNA) function in tumors can advance our diagnostic and prognostic capabilities. Here, we describe the development of technology for the profiling of miRNA expression in the tumors of live animals. PROCEDURES: The approach is based on miRNA nanosensors consisting of sensor oligonucleotides conjugated to magnetic nanoparticles for systemic delivery. Feasibility was demonstrated for the detection of miR-10b, implicated in epithelial to mesenchymal transition and the development of metastasis. The miR-10b nanosensor was tested in vivo in two mouse models of cancer. In the first model, mice were implanted subcutaneously with MDA-MB-231-luc-D3H2LN tumors, in which miR-10b was inhibited. In the second model, mice were implanted bilaterally with metastatic MDA-MB-231 and nonmetastatic MCF-7 cells. The nanosensors were injected intravenously, and fluorescence intensity in the tumors was monitored over time. RESULTS: We showed that the described nanosensors are capable of discriminating between tumors based on their expression of miR-10b. Radiant efficiency was higher in the miR-10b-active tumors than in the miR-10b-inhibited tumors and in the MDA-MB-231 tumors relative to the MCF-7 tumors. CONCLUSIONS: The described technology provides an important tool that could be used to answer questions about microRNA function in cancer.
PURPOSE: The development of tools for the analysis of microRNA (miRNA) function in tumors can advance our diagnostic and prognostic capabilities. Here, we describe the development of technology for the profiling of miRNA expression in the tumors of live animals. PROCEDURES: The approach is based on miRNA nanosensors consisting of sensor oligonucleotides conjugated to magnetic nanoparticles for systemic delivery. Feasibility was demonstrated for the detection of miR-10b, implicated in epithelial to mesenchymal transition and the development of metastasis. The miR-10b nanosensor was tested in vivo in two mouse models of cancer. In the first model, mice were implanted subcutaneously with MDA-MB-231-luc-D3H2LN tumors, in which miR-10b was inhibited. In the second model, mice were implanted bilaterally with metastatic MDA-MB-231 and nonmetastatic MCF-7 cells. The nanosensors were injected intravenously, and fluorescence intensity in the tumors was monitored over time. RESULTS: We showed that the described nanosensors are capable of discriminating between tumors based on their expression of miR-10b. Radiant efficiency was higher in the miR-10b-active tumors than in the miR-10b-inhibited tumors and in the MDA-MB-231tumors relative to the MCF-7 tumors. CONCLUSIONS: The described technology provides an important tool that could be used to answer questions about microRNA function in cancer.
Authors: Sven C A Michel; Thomas M Keller; Johannes M Fröhlich; Daniel Fink; Rosmarie Caduff; Burkhardt Seifert; Borut Marincek; Rahel A Kubik-Huch Journal: Radiology Date: 2002-11 Impact factor: 11.105
Authors: Aglaya G Iyevleva; Ekatherina Sh Kuligina; Nathalia V Mitiushkina; Alexandr V Togo; Yoshio Miki; Evgeny N Imyanitov Journal: Breast Cancer Res Treat Date: 2011-11-05 Impact factor: 4.872
Authors: Mukesh G Harisinghani; Jelle Barentsz; Peter F Hahn; Willem M Deserno; Shahin Tabatabaei; Christine Hulsbergen van de Kaa; Jean de la Rosette; Ralph Weissleder Journal: N Engl J Med Date: 2003-06-19 Impact factor: 91.245